Appointment of a Non-Executive Director

18 November 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the 'Company")

Appointment of a Non-Executive Director

Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that it has appointed, with immediate effect, Jean-Yves Pavée as a Non-Executive Director; nominated by Abbott (NYSE: ABT).

Jean-Yves Pavée is Senior Vice President, Developed Markets for Abbott's Established Products Division. He was appointed to his role in July 2013. Previously, he served as Divisional Vice President, EMEA East, and Division Vice President, Pharmaceuticals, Europe South. He joined Abbott in 1992.

Peter Jensen Chairman of Allergy Therapeutics commented:

"We are delighted towelcome Jean-Yves to the Board.  He brings extensive industry experience, which will be invaluable toour Company as we continue to execute our global strategy."

Additional information regarding Jean-Yves Pavée:

Full name and age: Jean-Yves Frédéric Georges André Pavée-Callu, aged 51

There are no further disclosures required under Schedule Two paragraph (g) of the AIM rules.

For further information

Note to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. Ithas a growing business achieving revenue in thelast financial yearof £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into theEmerging markets